For more than 20 years, Gary Veron has advised clients regarding the development, approval, and marketing of pharmaceutical and biological products. Gary is committed to helping life science companies successfully manage legal and business complexities to achieve their goals. His practice focuses on Hatch-Waxman Act, biosimilars, and life cycle management issues.

With a degree in biology and prior experience as a registered patent attorney, Gary understands how the science fits in the legal framework. In particular, he has considerable experience handling issues that occur at the intersection of FDA and intellectual property laws. He draws on his unique background to counsel clients regarding comprehensive development strategies, including market exclusivity periods, Orange Book issues, and therapeutic equivalence determinations. Gary assists clients in resolving the novel issues raised in biosimilar and 505(b)(2) applications.

Gary also has experience negotiating technology transfer and license agreements and managing patent prosecution matters. Before joining Hogan Lovells, Gary practiced both food and drug law and patent law at another international law firm. His experience includes serving as a Technology Development Specialist at the National Institutes of Health (NIH), where he was the intellectual property manager for four NIH institutes.

Gary's experience and skills have earned recognition in the Best Lawyers in America (FDA Law) and Legal 500 USA.